CompletedPhase 3

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

Belgium503 participantsStarted 2006-05

Plain-language summary

This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Hormone refractory prostate cancer within 6 months of diagnosis, OR locally advanced (non-metastasized) pancreatic cancer within 3 months of diagnosis, OR non-small-cell lung cancer within 3 months of stage IIIB. Exclusion criteria: * Life expectancy of \<3 months. * Poor performance status (Karnofsky \<60). * Need to be on anticoagulants. * Use of nadroparin (a low molecular weight heparin) for any reason including a history of heparin-induced thrombocytopenia. * Have brain metastasis. * At a high risk of bleeding or have a platelet count \<50,000/mm3. * Have very poor kidney function.

What they're measuring

Death due to all causes at study end (patients will be followed until at least Week 46 after randomization).

Timeframe: AT least 46 weeks after randomization

Trial details

NCT IDNCT00312013

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-07

View on ClinicalTrials.gov More Thrombosis, Venous trials